Kaplan-Meier curves comparing overall survival for combination... | Download Scientific Diagram
Avastin® (bevacizumab) Clinical Trials | MCRC Treatment
First-line cetuximab improves the efficacy of subsequent bevacizumab for RAS wild-type left-sided metastatic colorectal cancer: an observational retrospective study | Scientific Reports
Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer | NEJM
Adding panitumumab vs. bevacizumab to chemotherapy extends OS in colorectal cancer subset
Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE) | Journal of Clinical Oncology
Avastin® (bevacizumab) Clinical Trials | MCRC Treatment
Bevacizumab with chemotherapy in patients with KRAS wild-type metastatic colorectal cancer: Czech registry data | Future Oncology
A) Progression-free survival (PFS) and (B) overall survival (OS) for... | Download Scientific Diagram
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study - The
Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated – NIVACOR trial (GOIRC-03-2018) | BMC Cancer | Full Text
Overall survival for colorectal cancer patients treated with FOLFIRI®... | Download Scientific Diagram
Multicenter phase II study of biweekly CAPIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer (JSWOG-C3 study) | International Journal of Clinical Oncology
Primary tumor location and survival in colorectal cancer: A retrospective cohort study
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial | British Journal of Cancer
When more is better: bevacizumab treatment for patients with ovarian cancer | Fred Hutchinson Cancer Center
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial - The Lancet Oncology
Kaplan-Meier Estimates of Progression-free and Overall Survival,... | Download Scientific Diagram
World-first confirmation of standard treatment for RAS wild-type colorectal cancer －Paper published in JAMA－ | National Cancer Center Japan
New Treatment Options for Colorectal Cancer
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial - The Lancet Oncology
SUNLIGHT trial meets primary endpoint in refractory metastatic CRC - Medical Conferences
Impact of Bevacizumab-containing Primary Treatment on Outcome of Recurrent Ovarian Cancer: An Italian Study | Anticancer Research
Figure 1 from Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies | Semantic Scholar
